No profile data available.
Acumen Pharmaceuticals, Inc. (ABOS) is a healthcare company in the brain and nerve treatment drugs industry, based in Newton, United States, with about 60 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$121.34 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $154.76 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$154.76 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Alpha Cognition Inc. (ACOG), Inhibikase Therapeutics, Inc. (IKT), PepGen Inc. (PEPG), Minerva Neurosciences, Inc. (NERV).